Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 92%
filed 2026-08-17
EX-99.3
This exhibit is a press release announcing Nasus Pharma's first-half 2026 financial results, including unaudited interim condensed consolidated balance sheets and statements of operations for the six months ended June 30, 2026. The disclosure includes key financial metrics (cash position of $11.9 million, R&D expenses of $2.6 million, net loss of $5.9 million) and clinical program updates. While the exhibit also mentions the appointment of Brendan O'Grady as CEO, the primary substance is the financial results announcement, making this an earnings_release rather than an exec_appointment event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-17
The filing discloses an operational update on Bitmine's cryptocurrency holdings and treasury strategy, including ETH accumulation progress (5.82 million tokens, 4.8% of total ETH supply), staking operations (5.07 million staked ETH generating projected $287M annualized rewards), and share repurchase activity (20.8M shares repurchased since July 2026 under a $4B program). While the press release contains forward-looking statements about the company's "Alchemy of 5%" ETH acquisition goal and MAVAN platform expansion, the core disclosure is an operational and strategic business update regarding the company's digital asset treasury and staking infrastructure—not a specific material event type (earnings, M&A, impairment, etc.). The material holdings ($11.4B in crypto and cash) and active share buyback program would affect a reasonable investor's assessment of the company's financial position and capital allocation strategy.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-08-17
EX-99.1
Almonty announced Board approval of a new share repurchase program authorizing the purchase of up to 14.4 million common shares (approximately 5% of outstanding shares) for an aggregate purchase price of up to US$300 million over a 36-month period. Share repurchase programs are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs" as explicitly stated in the taxonomy. The program is material to investors as it represents a significant capital allocation decision and shareholder value strategy.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
The 8-K discloses Item 2.02 (Results of Operations and Financial Condition) with a press release announcing AMC Robotics' financial results for Q2 2026 ended June 30, 2026. The filing includes detailed consolidated statements of operations, balance sheets, and cash flows, along with management commentary on revenue trends, gross margin expansion to 80%, and strategic initiatives. This is a standard quarterly earnings release material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
Pioneer Power Solutions issued a press release on August 17, 2026, announcing financial results for the second fiscal quarter ended June 30, 2026. The filing discloses Q2 2026 revenue of $5.0 million (down 40% YoY), net loss of $2.1 million, backlog growth to $18.4 million, and management's outlook for H2 2026 revenue of approximately $15 million. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-08-17
The filing discloses multiple material events: (1) entry into a $5M senior secured convertible note with an institutional investor (Item 1.01), (2) completion of an acquisition of a 9.9% equity interest in Lyken AI Computing for 1,674,480 restricted shares (Item 8.01 / Exhibit 99.1), and (3) appointment of a new CFO (Item 5.02). The most salient event is the acquisition of Lyken, which marks FingerMotion's "formal entry into the enterprise AI compute market" and represents a strategic M&A transaction. While the debt issuance is also material, the acquisition is the primary strategic event disclosed and would most significantly affect investor assessment of the company's direction and capital deployment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-17
EX-99.1
This press release announces pre-clinical research results showing that Aramchol (Galmed's SCD1 inhibitor) demonstrates a 3–4-fold increase in cell death when combined with enzalutamide in prostate cancer models. The disclosure is a material operational/strategic milestone for a clinical-stage biopharmaceutical company: it presents novel scientific data supporting a potential combination therapy strategy, identifies a large market opportunity (Xtandi's ~$6–8 billion annual sales), and indicates the company plans to initiate partnership discussions based on a recently submitted patent application. While not a discrete M&A transaction or earnings release, this represents a material advancement in the company's oncology pipeline and commercial strategy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-17
The filing discloses that the Form S-4 registration statement for the proposed business combination between Aureus Greenway Holdings Inc. and Autonomous Power Corporation (Powerus) was declared effective by the SEC on August 12, 2026. This is a material milestone in a merger transaction where Powerus will merge into an AGH subsidiary, with the combined company to be renamed Powerus Corporation and expected to close in Q4 2026. The effectiveness of the S-4 is a critical step toward completing this material acquisition/change of control.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-17
EX-99.1
RedCloud announced a three-year commercial agreement with Golomax and Picking Up in Argentina forecasting $20m in revenue to RedCloud and $1.2Bn in traded goods transacted through RedAI. This is a material strategic partnership representing a new route-to-market model (licensing intelligence to existing networks rather than building owned operations), with deployment of RedAI RAID technology and revenue-share arrangements. The agreement is operational and strategic in nature, distinct from M&A (no acquisition or change of control), and represents a significant business development milestone that would affect investor assessment of the company's growth trajectory and market expansion strategy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-17
Item 8.01
Ocean Power Technologies announced that its Board of Directors has initiated a review of strategic alternatives with the goal of maximizing stockholder value, retaining Bowen, Inc. as financial advisor. The press release explicitly states the Board will "consider a full range of potential alternatives" including those that could "accelerate growth, expand market access and strengthen financial position." While no definitive transaction has been approved, the initiation of a formal strategic review process—particularly one involving a financial advisor and explicitly contemplating M&A-type alternatives—constitutes a material disclosure of potential M&A activity that would affect a reasonable investor's assessment of the company's future direction and value.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-17
MicroVision entered into a securities purchase agreement on August 14, 2026, to issue 6,800,000 shares of common stock together with 6,800,000 warrants at $2.50 per unit, raising approximately $17.0 million in gross proceeds ($15.6 million net). This is a registered public offering of equity securities with warrants, disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The offering closed on August 17, 2026, and represents a dilutive equity issuance material to investors assessing the company's capital structure and ownership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
The filing discloses the appointment of Oscar Suarez as an independent director and Audit Committee Chair, effective August 17, 2026. The Board increased from five to six members to accommodate this appointment. Suarez brings over four decades of accounting, tax, and governance experience from Arthur Andersen, KPMG, and EY, making this a material governance event affecting the composition and oversight structure of the Board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
The filing discloses the appointment of Carol L. Brosgart, MD to Cocrystal Pharma's Board of Directors, effective August 12, 2026. The press release emphasizes her extensive experience in antiviral drug development, FDA approvals, and prior roles at major pharmaceutical companies (Gilead, Tobira), making this a material governance event affecting board composition and strategic direction at a clinical-stage biotech company.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-17
Item 3.03
This disclosure concerns a 1-for-20 reverse stock split approved by the Board and shareholders, effective August 20, 2026, implemented via a Certificate of Amendment to the Articles of Incorporation. The primary purpose stated is to regain compliance with Nasdaq's $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)). While the reverse split modifies shareholder rights (Item 3.03) and amends the Articles of Incorporation (Item 5.03), it is fundamentally a governance and capital structure action rather than a specific named event type. The materiality is high because the reverse split affects all shareholders' holdings and signals delisting risk mitigation, making it material to investor assessment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-17
The filing discloses entry into a Second Amendment to an Agreement and Plan of Merger and Reorganization with Gravitics, Inc., modifying the post-merger ownership structure such that Gravitics stockholders will own approximately 96.5% and the Company's stockholders will own approximately 3.5% of the combined company. This is a material modification to a merger transaction that fundamentally alters the deal economics and ownership allocation, triggering Item 1.01 disclosure of a material definitive agreement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
The 8-K discloses financial results for Perfect Moment's fiscal Q1 2027 (ended June 30, 2026) via Item 2.02 (Results of Operations and Financial Condition), with a press release attached as Exhibit 99.1. The press release contains detailed financial highlights, condensed consolidated statements of operations, balance sheet data, and management commentary on quarterly performance—all hallmarks of an earnings release.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-17
The filing discloses visual drill results from hole SMD-26-219 at the Selebi Main deposit in Botswana, extending a high-grade mineralized trend by approximately 450 metres. While assays are pending, the company reports thick intervals of semi-massive and massive sulphide mineralization consistent with previous drilling. This represents a material operational/exploration milestone for a mineral exploration company, disclosed under Item 7.01 (Regulation FD Disclosure) as a news release. The event is material to investors assessing the company's resource expansion potential, though it falls outside the specific named categories (not a formal resource estimate update, not a completed acquisition, not a restatement or impairment charge).
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-17
The filing discloses an amendment to existing debentures (Item 1.01) whereby the Company increased the principal amount of three notes by approximately $89,778 in aggregate and modified negative covenants, including relaxing cash/Bitcoin custody requirements from $100,000 to $3,500,000. While technically an amendment to existing debt rather than a new issuance, the material increase in principal obligations and covenant modifications constitute a material modification of direct financial obligations under Item 2.03, warranting classification as a debt-related event. The covenant waiver and principal increases are material to investors assessing the Company's financial obligations and creditworthiness.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 70%
filed 2026-08-17
Item 1.01
Fastly entered into a Fourth Amendment to its Credit Agreement on August 17, 2026, increasing the senior secured revolving credit facility commitments from $60.0 million to $100.0 million, extending the maturity date to August 17, 2029 with a conditional one-year extension option, reducing interest rates by 0.25%, and adjusting commitment fees. This material modification to the Company's credit arrangements creates a significant new direct financial obligation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-08-17
Item 1.01
HomeTrust Bancshares entered into a definitive Agreement and Plan of Merger with Blue Ridge Bankshares on August 16, 2026, whereby HomeTrust will acquire Blue Ridge in an all-stock transaction valued at approximately $448.1 million with an exchange ratio of 0.086 HomeTrust shares per Blue Ridge share. The transaction is expected to close in Q1 2027, subject to regulatory and shareholder approval, and will create a combined entity with over $7 billion in assets and 60+ locations across the Southeast.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-08-17
Item 8.01
The filing explicitly states "This current report on Form 8-K relates to a distribution made to holders of the Certificates issued by the Select Notes Trust LT 2004-1." This is a distribution to certificate holders of a trust vehicle, which constitutes a dividend or distribution event. While the Item 8.01 disclosure is largely boilerplate regarding underlying security issuers and SEC reporting requirements, the core triggering event is the distribution itself, which is material to certificate holders.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-08-17
Item 8.01
The filing discloses the entry into an underwriting agreement for the sale of mortgage pass-through certificates with an aggregate initial principal amount of $377,960,000 in publicly offered certificates, plus $68,672,750 in privately offered certificates, scheduled to close on August 25, 2026. This represents the creation of new direct financial obligations secured by a pool of 20 fixed-rate mortgage loans on multifamily properties. While this is a securitization structure rather than traditional debt issuance, the certificates constitute debt-like obligations backed by mortgage collateral and are rated by nationally recognized rating agencies, making this a material debt issuance event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-17
Item 7.01
Duos Technologies announced execution of five-year hosting service agreements with Axe Compute valued at over $500 million covering 55 MW of AI facility capacity. This represents a material commercial contract and strategic business milestone for the company's AI infrastructure strategy, but does not fit neatly into the specific M&A, debt, or other defined financial event categories. The disclosure is a significant operational/strategic business development that would affect a reasonable investor's assessment of the company's growth prospects and revenue pipeline.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-17
EX-99.1
Trinity Biotech announced a strategic collaboration agreement between its Trinovium subsidiary and Echelon Data Centres to develop advanced liquid cooling solutions for AI data center infrastructure. This is a material operational and strategic partnership that expands the company's addressable market into a high-growth sector (projected to grow from $4 billion in 2026 to $27 billion by 2033), leveraging Trinity Biotech's existing fluid manufacturing and analytical capabilities. While not a discrete M&A transaction, the collaboration represents a significant strategic initiative that would affect a reasonable investor's assessment of the company's growth prospects and business diversification.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-17
Item 8.01
News Corporation discloses ongoing execution of its $1 billion share repurchase program authorized July 15, 2025, with daily buy-back notifications to the ASX showing approximately $425.9 million in cumulative purchases to date across Class A and Class B common stock. Share repurchases constitute a form of capital return to shareholders and are classified as dividend_distribution events under the taxonomy, as they represent a return of capital to security holders.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-17
Item 2.01
Braemar Hotels & Resorts completed the sale of the 142-room Pier House Resort & Spa in Key West, Florida for $190.0 million in cash on August 12, 2026, pursuant to an Agreement of Purchase and Sale dated July 13, 2026. This is a material disposition of a significant hotel asset representing a substantial portion of the company's portfolio, with pro forma adjustments showing removal of $78.9 million in net hotel property value and $93.7 million in associated mortgage debt repayment. The transaction generated an estimated non-recurring gain of approximately $108.6 million and materially affects the company's balance sheet and operating results.
View raw filing on EDGAR →
6-K
Legal Other
confidence 75%
filed 2026-08-17
EX-99.1
The disclosure reports the outcome of a USFDA GMP inspection at Dr. Reddy's API manufacturing facility in the UK, classified as "Voluntary Action Indicated (VAI)" with the inspection officially closed. This is a regulatory matter involving a foreign regulatory agency (USFDA) and a manufacturing facility, which could affect product quality, compliance standing, and market access. While VAI is not the most severe classification, it signals regulatory findings requiring corrective action and is material to investors assessing operational and regulatory risk.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
Item 2.02
AMASS Brands issued a press release on August 17, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing net revenue of $5.6 million (up 2% YoY), gross profit of $1.5 million, and adjusted EBITDA of $(1.7) million. The filing also includes initial financial guidance for Q3, full-year 2026, and fiscal 2027. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-17
Item 1.01
Madison Air Solutions entered into a definitive Stock Purchase Agreement to acquire ebm-papst for an enterprise purchase price of EUR 4,775.0 million (approximately $5.4 billion). The transaction, expected to close by year-end 2026, is financed by UniCredit and Wells Fargo and is expected to nearly double the company's addressable market and be accretive to EPS in the first full year post-closing.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-17
Item 8.01
Strive announced a bitcoin purchase of 79 BTC at ~$63,231 per bitcoin during August 10-14, 2026, along with updated holdings of cash, bitcoin, STRC Stock, and share counts. This represents a material operational/treasury decision reflecting the company's stated Bitcoin treasury strategy, but does not fit neatly into specific event categories (not M&A, not a debt issuance, not a dilutive equity issuance, not a restatement or impairment). The disclosure is material to investors assessing the company's capital allocation and strategic direction, particularly given the forward-looking statements reference to "Bitcoin treasury strategies."
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-17
The 8-K explicitly states that on March 26, 2026, Corebridge entered into an "Agreement and Plan of Merger" with Equitable Holdings, Inc. and related entities. The filing is submitted to incorporate Equitable's audited and unaudited financial statements and pro forma combined financial information into a registration statement for purposes of the merger transaction. This is a material acquisition/merger activity requiring disclosure under Item 1.01 or 2.01.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-08-17
Item 7.01
This Item 7.01 disclosure announces the availability of an investor presentation in connection with a $39.4 million PIPE transaction and references a Schedule 14C filing. While the presentation itself is furnished under Regulation FD (non-filed disclosure), the underlying transaction—a private investment in public equity announced July 20, 2026—involves material capital raising and debt redemption. The disclosure is material to investors but does not fit neatly into a single taxonomy category: it is neither a completed M&A transaction (ma_activity), a debt issuance (debt_issuance), nor a dilutive equity issuance (dilutive_issuance) in the traditional sense, as the PIPE structure and its full terms are referenced in a separate Schedule 14C filing. The Item 7.01 disclosure itself is primarily an announcement of the presentation's availability rather than a substantive disclosure of the transaction's terms.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-17
EX-99.1
The exhibit announces the appointment of Caroline Levy, a veteran Wall Street consumer analyst with 30+ years of experience and current board member of Celsius Holdings, to Prenetics' Board of Directors as an independent director, with concurrent service on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. This is a material governance event affecting board composition and oversight structure.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-08-17
Item 8.01
This 8-K Item 8.01 discloses Ares Real Estate Income Trust's monthly NAV update as of July 31, 2026, including detailed portfolio composition, NAV per share calculations ($8.2554), leverage ratio (32%), and capital raising activity ($102 million gross proceeds). While the filing does not fit a specific financial event category (not earnings, debt issuance, dividend, impairment, or restatement), it is clearly a material financial disclosure that would affect a reasonable investor's assessment of the fund's net asset value, portfolio performance, and capital structure. The detailed valuation methodologies, property appraisals, and sensitivity analyses demonstrate this is substantive financial reporting beyond routine administrative disclosure.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-08-17
Item 8.01
This 8-K discloses the Company's monthly Net Asset Value (NAV) per share as of July 31, 2026 ($13.3499), along with detailed portfolio composition, leverage metrics, and distribution information. While NAV updates are routine for non-traded REITs, this disclosure materially affects investor valuation and pricing decisions, as the NAV directly determines the transaction price for share purchases and redemptions. The filing includes comprehensive asset and liability breakdowns, occupancy metrics, and capital-raising activity that would inform a reasonable investor's assessment of the fund's financial condition.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-08-17
Item 8.01
The filing discloses the Company's Net Asset Value (NAV) per share as of July 31, 2026, broken down by share class (Class J at $20.1595 and Class E at $20.2982), along with a detailed NAV calculation showing major asset and liability components. This is a routine financial disclosure of NAV, which is material to investors in this residential trust as it directly reflects the per-share value of their investment, but does not fit the specific categories of earnings release, impairment, debt issuance, or other named financial events.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-08-17
Item 8.01
This 8-K discloses the Company's monthly NAV calculation as of July 31, 2026 ($9.83 per share/OP Unit), which serves as the transaction price for share issuances, redemptions, and distribution reinvestments. The filing includes detailed valuation methodology, property portfolio composition (55 properties, 94% leased, 30% levered), and August 2026 distributions. While routine for a non-traded REIT's monthly NAV disclosure, the NAV is material to investors as it directly determines pricing for ongoing share offerings and redemptions, and the filing includes sensitivity analyses showing how valuation assumptions impact property values.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
The Board of Directors appointed Sarah Watterson as a Class III independent director effective August 17, 2026, expanding the Board from nine to ten members. The appointment includes compensatory arrangements consisting of an annual cash retainer of $75,000 and an RSU grant of $215,000.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-17
The 6-K discloses the appointment of Andrea Lupo Lanzara as a Class III director of Scorpio Tankers Inc., effective August 17, 2026, to fill a vacancy created by the resignation of Marianne Økland. While both a departure and an appointment occur, the principal disclosed action is the appointment of a new director to the board, making exec_appointment the appropriate classification. Board-level director appointments are material to investors' assessment of governance and leadership.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-17
Item 1.01
DocGo entered into a definitive Agreement and Plan of Merger to acquire Hicuity Health, a virtual care provider. The transaction involves DocGo's subsidiary merging with Hicuity, with Hicuity surviving as a wholly owned subsidiary, for consideration consisting of 2.0% of DocGo's fully diluted common stock at closing plus up to 3.5% contingent earnout shares, plus assumption of approximately $52 million in existing indebtedness.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
Item 2.02
DocGo announced Q2 2026 earnings results (ended June 30, 2026) reporting total revenue of $73.4 million, net loss of $18.0 million, and adjusted EBITDA of ($6.3) million, along with revised full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-17
Item 8.01
The filing discloses that Lexaria has cured a Nasdaq bid price deficiency and regained compliance with Listing Rule 5550(a)(2), resulting in cancellation of a previously requested delisting hearing. While the news is positive (cure achieved), the disclosure itself centers on a delisting risk event—the company was previously non-compliant with continued listing standards and faced potential delisting. This is material to investors as it directly affects the registrant's exchange listing status.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-08-17
This 6-K furnishes a press release announcing positive Phase III trial results (SAFFRON) for Tagrisso plus Orpathys in EGFRm lung cancer, showing statistically significant improvements in progression-free and overall survival. While technically a clinical trial result rather than financial earnings, this disclosure of material clinical efficacy data for a key oncology product would affect a reasonable investor's assessment of the registrant's pipeline and commercial prospects. The announcement emphasizes this as "the first global Phase III trial to show significant progression-free and overall survival benefits in this setting," reinforcing its materiality to the company's oncology strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-17
AstraZeneca announced discontinuation of the eVOLVE-Lung02 Phase III trial of volrustomig based on an Independent Data Monitoring Committee recommendation that the drug combination was unlikely to meet dual primary endpoints (PFS and OS) in the primary analysis population. This is a material clinical development setback affecting a late-stage oncology program, but does not fit the specific event categories (not an earnings release, impairment charge, or litigation). It is clearly operational—a strategic decision to halt a clinical trial—making operational_other the appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-17
This 6-K discloses positive Phase III trial results for Enhertu (trastuzumab deruxtecan) in first-line HER2-mutant lung cancer, showing statistically significant improvement in progression-free survival versus standard of care in the DESTINY-Lung04 trial. While this is a clinical milestone for an oncology product, it does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or financial obligation). The disclosure represents a material operational/clinical development milestone that would affect investor assessment of the company's pipeline and commercial prospects, particularly as Enhertu is already approved in multiple indications and this result supports potential label expansion to first-line treatment.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-17
Guardian Metal Resources announced the exercise of warrants over 3,989,027 new ordinary shares at 40 pence per share, raising £1,595,610.80. This represents a dilutive issuance of equity securities that increases the company's share count from approximately 194.8 million to 198.8 million shares. The warrant exercise is material to investors as it affects ownership dilution and the company's capital structure.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 98%
filed 2026-08-17
HSBC Holdings plc issued SGD 450 million in 2.950% Fixed Rate Resettable Notes due 2032 on 17 August 2026 under its Debt Issuance Programme. The notes were admitted to trading on the Main Market of the London Stock Exchange. This is a straightforward debt issuance creating a new direct financial obligation and is material to investors assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-17
Item 5.07
This Item 5.07 disclosure reports the results of CEL-SCI's annual shareholder meeting held on August 14, 2026, including election of three directors (Geert Kersten, Bruno Baillavoine, Robert Watson) and approval of six proposals: adoption of the 2026 Non-Qualified Stock Option Plan, adoption of the 2026 Stock Bonus Plan, advisory vote on executive compensation, advisory vote frequency, and ratification of BDO USA, LLP as independent auditor. The tabulation of votes cast for each proposal is provided in full, which is the core disclosure required by Item 5.07.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
Item 2.02
WidePoint Corporation disclosed financial results for the six-month and quarter periods ended June 30, 2026 via a press release (Exhibit 99.2) and earnings call transcript (Exhibit 99.1) filed under Item 2.02. This is a standard earnings release disclosure announcing quarterly and interim financial results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-17
Item 2.02
Cloudastructure reported Q2 2026 financial results with quarterly revenue of $1.2 million (13% YoY growth), subscription revenue growth of 164% YoY, gross profit of $610,000 (53% YoY growth), and narrowed net loss to $1.7 million.
View raw filing on EDGAR →